Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 20 |
| Active Pipeline (Recruiting Now) | 13 (7) |
| Completed vs Stopped Early | 1 / 5 (25.0%) |
| Median Closed Actual Enrollment | 22 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06492837 | Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients | Phase II | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Fondazione Italiana Linfomi - ETS Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.